Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma (Q40227957)

18 September 2017

title

Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma (English)

1 reference

18 September 2017

Junichi Watanabe

1

1 reference

18 September 2017

Tsugitaka Natsume

series ordinal

2

1 reference

18 September 2017

Motohiro Kobayashi

series ordinal

3

1 reference

18 September 2017

publication date

25 September 2006

1 reference

18 September 2017

1 reference

18 September 2017

volume

97

1 reference

18 September 2017

issue

12

1 reference

18 September 2017

page(s)

1410-1416

1 reference

Vascular attack as a therapeutic strategy for cancer

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Targeting tumor vasculature with homing peptides from phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Genes expressed in human tumor endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Enhanced antitumor activities of TZT-1027 against TNF-alpha or IL-6 secreting Lewis lung carcinoma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

ZD6126: a novel small molecule vascular targeting agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Vinca alkaloids: anti-vascular effects in a murine tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Phase I trial of combretastatin a-4 phosphate with carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

Vascular-targeting therapies for treatment of malignant disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2006.00330.X

10.1111/J.1349-7006.2006.00330.X

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference